Merck shows signs of life in consumer health with new promo campaign

Tracy Staton Merck & Co. hasn't spent huge amounts of time and resources pushing its consumer health business. While other Big Pharmas like Sanofi ($ SNY) and GlaxoSmithKline ...

Merck wins FDA nod for new Zetia-Lipitor combo, despite lack of outcomes benefit

Tracy Staton Merck will soon launch a new cholesterol combo that melds its Zetia drug with generic Lipitor. The Zetia-plus-statin approach isn't new, of course; Merck already sells ...

Biotech Symphogen tacks on $53.7M to big venture round after Merck Serono deal

Ryan McBride Symphogen has replenished its coffers with €41 million ($ 53.7 million) as the Danish biotech makes progress with next-generation antibody drugs for treating cancer. ...

Merck buddies up to Scripps spinout Abide in $430M diabetes partnership

John Carroll Yesterday Merck's top executives spent a considerable amount of time trying to reassure analysts that the Big Pharma company is actively engaged in the hunt for new ...

Merck spotlights new deals, R&D review as demands to rebuild pipeline grow

John Carroll Merck CEO Kenneth Frazier Merck ($ MRK) managed to disappoint just about everyone this morning, cutting its full-year earnings expectations as generics eat up ...

Merck wins bellwether Fosamax femur-fracture trial

Tracy Staton The jury in the latest Fosamax trial has spoken, and it spoke for Merck ($ MRK). In a federal court in New Jersey, the panel determined that plaintiff Bernadette Glynn's ...

Giants team on diabetes as Merck partners with Pfizer on SGLT2 combo

John Carroll Jockeying for a leading position in the high-stakes race to develop a new generation of blockbuster diabetes drugs, Merck ($ MRK) is hitching a ride with Pfizer’s ...

Merck nabs ‘breakthrough’ label for anti-melanoma drug

Tracy Staton Merck ($ MRK) won the FDA's "Breakthrough Therapy" tag for its experimental antibody drug lambrolizumab, aimed at advanced melanoma. The designation was ...

Merck scores ‘breakthrough’ status from FDA for immunotherapy against melanoma

Ryan McBride Merck ($ MRK) has a shot at a speedy development path for lambrolizumab. The FDA has pinned a "Breakthrough Therapy" tag on the experimental antibody drug for ...

Bristol-Myers rebounds on hep C front with new Merck partnership

John Carroll Like most of its new drug programs in recent years, Merck's ($ MRK) work on new hepatitis C drugs has never quite paid off as hoped. Now it's taken its lead clinical-stage ...

Merck CEO snags 16% raise to $15.5M, in year of ‘significant hurdles’

Tracy Staton Merck CEO Kenneth Frazier Merck ($ MRK) CEO Kenneth Frazier scored a 16% raise for 2012. In a normal year, that might be a normal increase in compensation for ...

Merck peddles a pair of neuroscience programs to Baltimore biotech

Ryan McBride Cerecor, a Baltimore-based biotech focused on neuroscience, has picked up two CNS programs from the U.S. drug giant Merck ($ MRK). The biotech outfit acquired exclusive ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS